Similar articles for PMID: 14600592

Year	Number of Results
1982	1
1988	2
1989	1
1990	5
1991	1
1992	6
1993	3
1994	7
1995	6
1996	12
1997	13
1998	13
1999	13
2000	12
2001	18
2002	15
2003	25
2004	17
2005	17
2006	9
2007	12
2008	17
2009	18
2010	4
2011	6
2012	10
2013	6
2014	3
2015	7
2016	5
2017	3
2018	7
2019	1
2020	2
2021	6
2022	7
2023	2
2024	0

1

Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.

Choong PF, Nadesapillai AP. Choong PF, et al. Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S46-58. doi: 10.1097/01.blo.0000093845.72468.bd. Clin Orthop Relat Res. 2003. PMID: 14600592 Review.

2

Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.

Albo D, Berger DH, Rothman VL, Tuszynski GP. Albo D, et al. J Surg Res. 1999 Apr;82(2):331-8. doi: 10.1006/jsre.1998.5578. J Surg Res. 1999. PMID: 10090848

3

Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.

Plesner T, Behrendt N, Ploug M. Plesner T, et al. Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review.

4

Evolving role of uPA/uPAR system in human cancers.

Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Dass K, et al. Cancer Treat Rev. 2008 Apr;34(2):122-36. doi: 10.1016/j.ctrv.2007.10.005. Epub 2007 Dec 26. Cancer Treat Rev. 2008. PMID: 18162327 Review.

5

Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.

He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li K, Dong JH, Li X. He Y, et al. Clin Cancer Res. 2007 Jun 1;13(11):3115-24. doi: 10.1158/1078-0432.CCR-06-2088. Clin Cancer Res. 2007. PMID: 17545513

6

Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.

Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Bauer TW, et al. Cancer Res. 2005 Sep 1;65(17):7775-81. doi: 10.1158/0008-5472.CAN-05-0946. Cancer Res. 2005. PMID: 16140945

7

The role of the plasminogen activation system in angiogenesis and metastasis.

Rabbani SA, Mazar AP. Rabbani SA, et al. Surg Oncol Clin N Am. 2001 Apr;10(2):393-415, x. Surg Oncol Clin N Am. 2001. PMID: 11382594 Review.

8

Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.

Xing RH, Mazar A, Henkin J, Rabbani SA. Xing RH, et al. Cancer Res. 1997 Aug 15;57(16):3585-93. Cancer Res. 1997. PMID: 9270032

9

Urokinase-type plasminogen activator system and breast cancer (Review).

Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Han B, et al. Oncol Rep. 2005 Jul;14(1):105-12. Oncol Rep. 2005. PMID: 15944776 Review.

10

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.

Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA. Meijer-van Gelder ME, et al. Cancer Res. 2004 Jul 1;64(13):4563-8. doi: 10.1158/0008-5472.CAN-03-3848. Cancer Res. 2004. PMID: 15231667

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

300 results

Results by year